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Properties and action mechanisms
of intravenous gammaglobulin
Propriedades e mecanismos de ação da gamaglobulina intravenosa
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ABSTRACT
Intravenous immunoglobulins (IVIG) preparations have been used as a substitutive therapy for primary
and secondary immunodeficiencies for many years; now it is well know that IVIG can have two other
important and opposite functions: pro and anti-inflammatory, depending on its concentration. Low doses
of IVIG exert proinflammatory activities, that require complement activation or binding via Fc fragment of
IgG to IgG Fcγ specific receptors present on effector cells of innate immunity. On the other hand, admin-
istration of high IVIG doses has anti-inflammatory activity. This manuscript presents a revision of how
IVIG IgG mediated this effects, how and upon which cells from the immune system acts, their capacity to
scavenging complement fragments, the recently demonstrated anti-inflammatory activity of variable mi-
nor sialylated portion of IgG molecules and finally, the importance of genetic variation and expression of
Fcγ receptors. To comprehend the mechanism of action of IVIG is fundamental, not only to obtain further
improvements on therapeutic effectiveness, but also to discover new and unexpected capacities of this
biological bomb known as IVIG.
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Introduction
Human immunoglobulin was used for the first
time in 1950 as a substitutive therapy in a patient with
primary agammaglobulinemia.1 It was not until the
1980s when improvements on the plasmatic fractioning
allow to develop molecules with an intravenous use
(IVIG), allowing a much larger amount of infusion and
therefore a wider therapeutic role than the IDP, ap-
plied, as well, in an important number of autoimmune
diseases, inflammatory disorders and a wide range of
off-label indications.2 Gamma globulin is made from
human plasma and therefore its production is limited,
affecting its price and making it an expensive good. It
is a safe drug, suffering multiple viral inactivation proc-
esses, increasingly stringent, but not exempt of some
risks, not only intrinsic to the product but also individual
features of the patient, so it should be used under strict
conditions with a clear therapeutic indication.3
IVIG contain polyspecific and polyclonal immu-
noglobulins, derived from fractioned pools of plasma
from hundreds of healthy donors. They are constituted
almost exclusively of IgG molecules. In the IVIGs one
can detect antibodies to foreign antigens, natural
1. Servei d’Immunología. Hospital Universitari Son Espases. Pal-
ma de Mallorca. Spain.
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autoantibodies and to idiotypic antibodies. The first
IVIG application was as a substitutive therapy in pri-
mary and secondary immunodeficiencies. Nowadays
we know the importance of pro and anti-inflamma-




The mechanism of action as a substitutive mol-
ecule in primary and secondary immunodeficiencies
has been comprehended for many years now.4 The
IgG obtained from the plasma fractioning of hundreds
of normal individuals, have the intrinsic capacity to
recognize and eliminate foreign and pathogen specific
antigens, when infused to a patient lacking this immu-
noglobulin.
Pro and anti-inflammatory activities
IgG molecules have been able to produce pro
and anti-inflammatory effects depending upon its con-
centration. Infusion of high doses of IVIG has an im-
portant anti-inflammatory role and represents an effi-
cient treatment for many autoimmune diseases.  It is
well known that the use of IVIG therapy is licensed
for idiopathic trombocytopenia purpura, Kawasaki dis-
eases between others and the off-label used has in-
crease during the years. Several mechanisms could
explain the anti-inflammatory activity of IVIg, but by
now the most relevant contributor to this activities are
the Fc fragments of IgG.5,6 The neonatal FcR (FcRn)
is an important regulator of the IgG function, they bind
to the CH3 domain of IgG in acidic conditions. The
importance of the FcRn receptor lies upon it ensuring
the characteristic long half-life of IgG (2-3 weeks); if
FcRn is not present the IgG half-life moves for a few
hours and lowers the antigen-specific IgG capacity
bind to the target. Blokage of IgG FcRn is a system to
interfere with pro-inflamatory activity of IgG. It is also
know that blocking FcγR interferes with the pro-in-
flammatory activity of IgG in many autoimmune dis-
eases. Moreover, in vivo studies demonstrated that the
sugar chain attached to the CH2 IgG domains shows
and important anti-inflammatory activity, present and
active in IVIG treatments. The Fcγ receptor with anti-
inflammatory activity was the inhibitory FcγRIIB, the
upregulation of this receptor was another way to in-
hibit the pro- inflammatory activity of IgG.
The pro-inflammatory activity of low IVIG
doses needs complement activation or union of IgG
Fc fragments to the FcγR presents in cells of the in-
nate immune system; after, activation of different sig-
nalling pathways occurs, intracellular calcium increases
and cell activation takes place.
Impact of IVIG on immune function
Recent observations demonstrated the effects
of IVIG therapy on  different cells of the immune sys-
tem, dendritic cell (DC), monocyte/macrophages,
granulocytes, natural killer (NK) and T and B lym-
phocytes, belongins to  adaptive as well as in innate
immune responses.7
At a dose used to treat autoimmune or inflam-
matory diseases (high doses), IVIG inhibits the differ-
entiation and maturation of DC cells; expression of
HLA, CD80 and CD86, essential for a suitable anti-
gen presentation to T cells, is inhibited by IVIG, this
could be an explanation to the positive activity of IVIG
therapy in Lupus eriythematosus and other autoim-
mune and inflammatory diseases as chronic inflam-
matory demyelinating polyradiculoneuropathy.8 Nev-
ertheless, an opposite action seems to be the result of
lower IVIG doses, when used as substitutive therapy
in primary immunodeficiencies; common variable im-
munodeficiency (CVID) patients, presented repetitive
infections and abnormal susceptibility to autoimmune
diseases, associated to impaired DC functions. IVIG
infusions partially restored immature DC phenotypes,
and up regulated the expression of CD40, CD80 and
CD86 molecules in CVID patients. X-linked agam-
maglobulinaemia (XLA) patients presented immature
DC populations, an addition of IVIG to autologous XLA
serum, naturally devoided of immunoglobulins, partially
restores the characteristics of a mature DC pheno-
type, increasing the expression of maturation related
molecules. This research suggests the importance of
immunoglobulin on the correct functioning of the DC.
During this process, anti-CD40 antibodies found in IVG
partially intervene.9
IVIG also exert their anti-inflammatory activity
through monocytes and macrophages; one mechanism
is inducing IL-1 antagonist receptor production (IL-
1RA), a potent anti-inflammatory molecule by
monocytes, that would consequently block IL-1. IVIG
also lowers serum levels of tumour necrosis factor
(TNF-alpha) and IL-1β, and modified the transcrip-
tion of different inflammatory genes as FcγRs and the
heterocomplex S100A8/A9 8.10
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IVIG effects on adaptive immune response was
mediated through T and B lymphocytes. These ef-
fects not only included the Fcγ blockade, but also a
possible suppression of autoreactive B lymphocytes
and the  neutralization of  survival and proliferation B
cell factors as B cell activating factor (BAFF) or the
proliferation-inducing ligand (APRIL).
Paramount control mechanisms of autoimmune
phenomena, were induced trough IVIG- B lymphocytes
interaction. As example, IVIG induce de novo pro-
duction of IgG antibodies against different self and
non self antigens derived from a only one individual B
cell subset. The interaction of anti-idiotypic antibodies
with IgG or IgM present in the B cell membrane may
down- regulated autoantibodies production.11 Recent
reports confirm previous data on blood B an NK cell
decrease after IVIG infusions in women with recur-
rent spontaneous abortion, modulation of LFA-1 and
or restricted treatment effects on pregnant women
immune system was described.12 In another hand it is
s also demonstrated in vitro, that IVIG induce the dif-
ferentiation of B lymphocytes and IgG secretion.13
It is well know that IVIG supress many T cell
functions. How this supressive effect is mediated has
not been fully elucidated, two mechanism affecting
the supressive effects of Tregs were recently de-
scribed, the expansion of CD4+CD25+ FOXP3+ T
cells and an important increase in their  suppressive
activity, after IVIG infusion.14
It is well known that IVIG interact with multi-
ple cells and molecules from the immune system, in-
nate and adaptive immunity are involved and that makes
clear support to the beneficial IVIG treatment effects.
Scavenging of complement products by IVIG,
is well established, and is present in all four IgG sub-
classes. Binding to potentially dangerous complement
fragments to IgG molecules prevents the deposition
of these fragments on their target tissues and inhibits
secondary tissue destruction together with inflamma-
tion phenomena.15
Recently, it was demonstrated that pro and anti-
inflammatory activities of IVIG are related to the spe-
cific sugar moity residues attached to the constant
domain of Fc IgG fragments. The number of
glycosylation variants present on IgG molecules, their
function and which pathways intervene in these ac-
tivities are currently being unveiled and may add new
capacities to this increasingly surprising proteins.16
Conclusions
Knowledge of the mechanisms of action and
properties of IVIG has increase exponentially in re-
cent years; describing their pro and anti-inflammatory
activities have opened the possibility of new thera-
peutic applications, the production of more effective
molecules and, in a near future, an emerging but real
production of recombinant IVIG products. These old
folks named IVIG have surely in store some new and
interesting therapeutic applications, free of significant
side effects.
The autor akcnowledges the support of
Grifols which has made it possible the prepara-
tion of this manuscript
RESUMO
As preparações de imunoglobulinas intravenosas (IVIG) têm sido utilizadas como terapia substitutiva
para imunodeficiências primárias e secundárias durante muitos anos; agora é sabido que a IVIG pode
ter duas outras funções importantes e opostas: pró e anti-inflamatória, dependendo da sua concentra-
ção. Em baixas doses a IVIG exerce atividades pró-inflamatórias, que requerem uma ativação do com-
plemento ou uma ligação via fragmento Fc de IgG para IgG Fcγ receptores específicos presentes nas
células efetoras da imunidade inata. Doutro lado, a administração de altas doses de IVIG provoca uma
atividade anti-inflamatória. Este manuscrito apresenta uma revisão de como a IVIG IgG mediou nestes
efeitos, cómo e sobre quais celulas do Sistema imune atua, a sua capacidade para limparem fragmen-
tos do complemento, a atividade anti-inflamatória recentemente demostrada de porção sializada menor
variável de moléculas de IgG e, finalmente, a importância da variação genética e expressão de recepto-
res Fcγ. Conocer o mecanismo de ação da IVIG é fundamental para obtermos, não só uma melhoria na
eficácia terapêutica, mais também para descobrirmos novas e surpreendentes capacidades desta
bomba biológica chamada IVIG.
Palavras-chave: Síndromes de Deficiência Imunológica. Gamaglobulina. Terapia de Reposição. Fun-
ção Imunológica.
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